Skip to main content

Advertisement

Table 2 Priority setting criteria. Main sources

From: Systematic review for the development of a pharmaceutical and medical products prioritization framework

Domain Considered criteria Alternative categorizations / subgroupings
Need for intervention -Severity of the disease / condition Target disease
- Population size - Severity of the disease
-Unmet need / availability of alternatives -Determinants of the disease
-Burden of illness / threat to life
-Economic burden of the disease
-Epidemiology
Therapeutic context
-Therapeutic alternatives / need not met
-Need
-Clinical practice guidelines and protocols
-Existing use
Health results -Benefits in health / clinical Clinical benefits
-Efficacy / Effectiveness - General clinical benefits
- Safety / tolerability -Effect on mortality
-Health perceived by the patient -Effect on longevity
-Quality of care -Effect on quality of life
Health perceived by the patient:
-Quality of life
- Autonomy
- Impact on dignity
- Improved use / administration
Adequacy
- Efficiency and safety
- Effectiveness
Response level
- Quality of care received by the patient
- Burden of disease
Type of benefit of the intervention -Preventive benefits  
-Therapeutic benefits
Economic consequences / economic impact -Costs of the intervention Efficiency
- Medical / health costs - Cost effectiveness / benefit
- Non-medical costs (productivity, cost, patients, caregivers) - Budget impact
-Impoverishment for the patient - Costs
- Budget impact Financing
-Financial impact - Unit cost
-Impact on productivity - Budget impact
-Impact on other services - Financing agent
-Efficiency and opportunity cost Cost of opportunity and affordability (context-dependent criteria)
-Cost-effectiveness - Opportunity cost and if the system can afford it
Existing knowledge about the intervention / Quality and uncertainty of the evidence -Evidence available Other considerations
-Quality of the evidence Quality of clinical and economic evidence
-Relevance of the evidence Consistency with strategic aspects
-Uncertainty of the evidence
-Expert consensus / clinical practice guidelines
Implementation and complexity of the intervention / Feasibility -Regulatory requirements / legislation
-Organizational requirements
-Technological requirements
-Requirements of personnel
-Training / personal skills requirements
-Information requirements
-Implementation flexibility
-Features of the intervention
-Appropriate use
-Barriers and acceptability
-Integration and efficiency of the system
-Sustainability
-Accessibility to the population
Ethics and justice -Population priorities Priority, ethics and justice
-Access - Low socioeconomic status
-Vulnerability - Children (0–5 years old or elderly)
-Utility - Subjects of productive age
-Solidarity - Women in productive age
-Ethics and moral aspects - Remote communities
- Therapeutic specific areas
- Response behavior
- Rare diseases
- Specific groups of patients
Equity
- General
- Accessibility
- Accessibility for the individual
Other ethical and social values
- Autonomy
- Value public health
- Impact in future generations
- Risk social and financial
- Catastrophic sanitary cost
- Economic productivity and care for third parties
- Rare diseases-Population priorities
Global context -Mandate and mission of the health system Governance / leadership
-Alignment with regulations and strategies - Congruence with prior prioritization
- Global priorities / alignment with priority lines (vulnerable groups, disabled, diseases, rare, etc.) - Cultural acceptability
-Financial Restriction - Political acceptability
-Incentives - Acceptability of interest groups
-Political aspects - Legal Barriers
- Historical aspects
-Cultural aspects
-Degree of innovation
-Collaboration and leadership
-Implementation of patients
-Pressure of different interest groups
-Environmental impact
  1. Main references used: EVIDEM tool [10, 11] and Guindo [13], Golan [14], Tanios [15], Tromp [16] studies